{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:02:49Z","timestamp":1781013769823,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health\/National Cancer Institute Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Health","award":["R25 5R25CA020449"],"award-info":[{"award-number":["R25 5R25CA020449"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11060-026-05626-z","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:51:39Z","timestamp":1779137499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings"],"prefix":"10.1007","volume":"178","author":[{"given":"Matthew","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke R. G.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Groeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-1681","authenticated-orcid":false,"given":"Nelson S.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"5626_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y","journal-title":"Curr Oncol Rep"},{"key":"5626_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"5626_CR3","doi-asserted-by":"publisher","first-page":"S795","DOI":"10.1016\/S1556-0864(21)02022-0","volume":"16","author":"W Cui","year":"2021","unstructured":"Cui W, Milner-Watts C, Saith S et al (2021) 180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19. J Thorac Oncol 16:S795. https:\/\/doi.org\/10.1016\/S1556-0864(21)02022-0","journal-title":"J Thorac Oncol"},{"key":"5626_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.trecan.2025.11.007","volume":"12","author":"M Valiente","year":"2026","unstructured":"Valiente M, Anders C, Boire A et al (2026) The evolving landscape of brain metastasis: II. Trends Cancer 12:116\u2013146. https:\/\/doi.org\/10.1016\/j.trecan.2025.11.007","journal-title":"Trends Cancer"},{"key":"5626_CR5","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.lanepe.2024.101181","volume":"49","author":"OE Yri","year":"2025","unstructured":"Yri OE, Astrup GL, Karlsson AT et al (2025) Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study. Lancet Reg Health - Europe 49:101181. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101181","journal-title":"Lancet Reg Health - Europe"},{"key":"5626_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/13696998.2021.1885418","volume":"24","author":"AM Kong","year":"2021","unstructured":"Kong AM, Pavilack M, Huo H et al (2021) Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. J Med Econ 24:328\u2013338. https:\/\/doi.org\/10.1080\/13696998.2021.1885418","journal-title":"J Med Econ"},{"key":"5626_CR7","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/cancers16142583","volume":"16","author":"M Zoghbi","year":"2024","unstructured":"Zoghbi M, Moussa MJ, Dagher J et al (2024) Brain Metastasis in the Emergency Department: Epidemiology, Presentation, Investigations, and Management. Cancers (Basel) 16:2583. https:\/\/doi.org\/10.3390\/cancers16142583","journal-title":"Cancers (Basel)"},{"key":"5626_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/nop\/npab029","volume":"8","author":"N Lamba","year":"2021","unstructured":"Lamba N, Catalano PJ, Whitehouse C et al (2021) Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neurooncol Pract 8:569\u2013580. https:\/\/doi.org\/10.1093\/nop\/npab029","journal-title":"Neurooncol Pract"},{"key":"5626_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM (2022) The Time Toxicity of Cancer Treatment. J Clin Oncol 40:1611\u20131615. https:\/\/doi.org\/10.1200\/JCO.21.02810","journal-title":"J Clin Oncol"},{"key":"5626_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.trecan.2023.01.006","volume":"9","author":"WV Johnson","year":"2023","unstructured":"Johnson WV, Blaes AH, Booth CM et al (2023) The unequal burden of time toxicity. Trends Cancer 9:373\u2013375. https:\/\/doi.org\/10.1016\/j.trecan.2023.01.006","journal-title":"Trends Cancer"},{"key":"5626_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/oncolo\/oyae187","volume":"29","author":"A Gupta","year":"2024","unstructured":"Gupta A, Brundage MD, Galica J et al (2024) Patients\u2019 considerations of time toxicity when assessing cancer treatments with marginal benefit. Oncologist 29:978\u2013985. https:\/\/doi.org\/10.1093\/oncolo\/oyae187","journal-title":"Oncologist"},{"key":"5626_CR12","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jamaoncol.2022.1928","volume":"8","author":"NS Moss","year":"2022","unstructured":"Moss NS, Beal K, Tabar V (2022) Brain Metastasis\u2014A Distinct Oncologic Disease Best Served by an Integrated Multidisciplinary Team Approach. JAMA Oncol 8:1252. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1928","journal-title":"JAMA Oncol"},{"key":"5626_CR13","doi-asserted-by":"publisher","first-page":"e2340654","DOI":"10.1001\/jamanetworkopen.2023.40654","volume":"6","author":"ED Bander","year":"2023","unstructured":"Bander ED, El Ahmadieh TY, Chen J et al (2023) Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases. JAMA Netw Open 6:e2340654. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.40654","journal-title":"JAMA Netw Open"},{"key":"5626_CR14","doi-asserted-by":"publisher","first-page":"e1732","DOI":"10.1200\/OP.22.00258","volume":"18","author":"NS Moss","year":"2022","unstructured":"Moss NS, El Ahmadieh TY, Brown S et al (2022) Integrated Multidisciplinary Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation. JCO Oncol Pract 18:e1732\u2013e1738. https:\/\/doi.org\/10.1200\/OP.22.00258","journal-title":"JCO Oncol Pract"},{"key":"5626_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11060-025-05274-9","volume":"176","author":"AJ Toth","year":"2025","unstructured":"Toth AJ, Robert SM, Fahy T et al (2025) Multidisciplinary review outperforms qualitative MR perfusion in distinguishing post-radiation brain metastasis recurrence versus radionecrosis. J Neurooncol 176:80. https:\/\/doi.org\/10.1007\/s11060-025-05274-9","journal-title":"J Neurooncol"},{"key":"5626_CR16","doi-asserted-by":"publisher","first-page":"114202","DOI":"10.1016\/j.ejca.2024.114202","volume":"208","author":"E Le Rhun","year":"2024","unstructured":"Le Rhun E, Weller M, Anders C et al (2024) Symptomatic melanoma brain metastases: A call for clear definitions and adoption of standardized tools. Eur J Cancer 208:114202. https:\/\/doi.org\/10.1016\/j.ejca.2024.114202","journal-title":"Eur J Cancer"},{"key":"5626_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L et al (2022) Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 12:265\u2013282. https:\/\/doi.org\/10.1016\/j.prro.2022.02.003","journal-title":"Pract Radiat Oncol"},{"key":"5626_CR18","doi-asserted-by":"crossref","unstructured":"Tahsin F, Bahr T, Shaw J et al (2024) The relationship between treatment burden and the use of telehealth technologies among patients with chronic conditions: A scoping review. Health Policy Technol 13","DOI":"10.1016\/j.hlpt.2024.100855"},{"key":"5626_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1186\/1471-2407-14-731","volume":"14","author":"M-C Cordes","year":"2014","unstructured":"Cordes M-C, Scherwath A, Ahmad T et al (2014) Distress, anxiety and depression in patients with brain metastases before and after radiotherapy. BMC Cancer 14:731. https:\/\/doi.org\/10.1186\/1471-2407-14-731","journal-title":"BMC Cancer"},{"key":"5626_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-0-387-69222-7_4","volume":"136","author":"HB Newton","year":"2007","unstructured":"Newton HB (2007) Symptom management and supportive care of the patient with brain metastases. Cancer Treat Res 136:53\u201373. https:\/\/doi.org\/10.1007\/978-0-387-69222-7_4","journal-title":"Cancer Treat Res"},{"key":"5626_CR21","doi-asserted-by":"publisher","first-page":"e433694","DOI":"10.1200\/EDBK_433694","volume":"44","author":"A Amouzegar","year":"2024","unstructured":"Amouzegar A, Haig S, Kahn AM et al (2024) Navigating the Complexities of Brain Metastases Management. Am Soc Clin Oncol Educ Book 44:e433694. https:\/\/doi.org\/10.1200\/EDBK_433694","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5626_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/theoncologist.2015-0328","volume":"21","author":"MJ McKee","year":"2016","unstructured":"McKee MJ, Keith K, Deal AM et al (2016) A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. Oncologist 21:16\u201320. https:\/\/doi.org\/10.1634\/theoncologist.2015-0328","journal-title":"Oncologist"},{"key":"5626_CR23","unstructured":"American Hospital Association (2025) The cost of caring. challenges facing America\u2019s hospitals in 2025"},{"key":"5626_CR24","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.22.01799","volume":"41","author":"HM Khan","year":"2023","unstructured":"Khan HM, Ramsey S, Shankaran V (2023) Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions. J Clin Oncol 41:3051\u20133058. https:\/\/doi.org\/10.1200\/JCO.22.01799","journal-title":"J Clin Oncol"},{"key":"5626_CR25","doi-asserted-by":"publisher","first-page":"e254689","DOI":"10.1001\/jamanetworkopen.2025.4689","volume":"8","author":"D Wasilewski","year":"2025","unstructured":"Wasilewski D, Araceli T, Rafaelian A et al (2025) Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection. JAMA Netw Open 8:e254689. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.4689","journal-title":"JAMA Netw Open"},{"key":"5626_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1227\/neu.0000000000002353","volume":"92","author":"SG Bowden","year":"2023","unstructured":"Bowden SG, Lopez Ramos CG, Cheaney B et al (2023) Response to Preoperative Dexamethasone Predicts Postoperative Neurological Improvement of Focal Neurological Deficits in Patients With Brain Metastases. Neurosurgery 92:1227\u20131233. https:\/\/doi.org\/10.1227\/neu.0000000000002353","journal-title":"Neurosurgery"},{"key":"5626_CR27","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","volume":"33","author":"X Lin","year":"2015","unstructured":"Lin X, DeAngelis LM (2015) Treatment of Brain Metastases. J Clin Oncol 33:3475\u20133484. https:\/\/doi.org\/10.1200\/JCO.2015.60.9503","journal-title":"J Clin Oncol"},{"key":"5626_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","volume":"96","author":"TC Ryken","year":"2010","unstructured":"Ryken TC, McDermott M, Robinson PD et al (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:103\u2013114. https:\/\/doi.org\/10.1007\/s11060-009-0057-4","journal-title":"J Neurooncol"},{"key":"5626_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21","volume":"40","author":"MA Vogelbaum","year":"2021","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al (2021) Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 40:492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21","journal-title":"J Clin Oncol"},{"key":"5626_CR30","doi-asserted-by":"publisher","unstructured":"Ene CI, Abi Faraj C, Beckham TH et al (2024) Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun 15. https:\/\/doi.org\/10.1038\/s41467-024-47998-8","DOI":"10.1038\/s41467-024-47998-8"},{"key":"5626_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuros\/nyz357","volume":"87","author":"DC Bastos","year":"2020","unstructured":"Bastos DC, de Rao A, Oliva G ICG, et al (2020) Predictors of Local Control of Brain Metastasis Treated With Laser Interstitial Thermal Therapy. Neurosurgery 87:112\u2013122. https:\/\/doi.org\/10.1093\/neuros\/nyz357","journal-title":"Neurosurgery"},{"key":"5626_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2022.05.008","volume":"36","author":"B Leyrat","year":"2022","unstructured":"Leyrat B, Khalill T, Lemaire J-J et al (2022) Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors. Clin Transl Radiat Oncol 36:1\u20138. https:\/\/doi.org\/10.1016\/j.ctro.2022.05.008","journal-title":"Clin Transl Radiat Oncol"},{"key":"5626_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.healthpol.2021.12.004","volume":"126","author":"K Jacobs","year":"2022","unstructured":"Jacobs K, Roman E, Lambert J et al (2022) Variability drivers of treatment costs in hospitals: A systematic review. Health Policy (New York) 126:75\u201386. https:\/\/doi.org\/10.1016\/j.healthpol.2021.12.004","journal-title":"Health Policy (New York)"},{"key":"5626_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13104-022-06014-2","volume":"15","author":"C Shen","year":"2022","unstructured":"Shen C, Moss JL (2022) Large variations in hospital pricing for standard procedures revealed. BMC Res Notes 15:129. https:\/\/doi.org\/10.1186\/s13104-022-06014-2","journal-title":"BMC Res Notes"},{"key":"5626_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1077558719853375","volume":"78","author":"M Panhans","year":"2021","unstructured":"Panhans M, Rosenbaum T, Wilson NE (2021) Prices for Medical Services Vary Within Hospitals, but Vary More Across Them. Med Care Res Rev 78:157\u2013172. https:\/\/doi.org\/10.1177\/1077558719853375","journal-title":"Med Care Res Rev"},{"key":"5626_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1377\/hlthaff.2019.01377","volume":"39","author":"ME Chernew","year":"2020","unstructured":"Chernew ME, Hicks AL, Shah SA (2020) Wide State-Level Variation In Commercial Health Care Prices Suggests Uneven Impact Of Price Regulation. Health Aff 39:791\u2013799. https:\/\/doi.org\/10.1377\/hlthaff.2019.01377","journal-title":"Health Aff"},{"key":"5626_CR37","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.21037\/jtd-22-697","volume":"15","author":"CH Fong","year":"2023","unstructured":"Fong CH, Meti N, Kruser T et al (2023) Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice. J Thorac Dis 15:4367\u20134378. https:\/\/doi.org\/10.21037\/jtd-22-697","journal-title":"J Thorac Dis"},{"key":"5626_CR38","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/j.jtocrr.2023.100607","volume":"4","author":"BS Imber","year":"2023","unstructured":"Imber BS, Sehgal R, Saganty R et al (2023) Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC. JTO Clin Res Rep 4:100607. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100607","journal-title":"JTO Clin Res Rep"},{"key":"5626_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","volume":"17","author":"NJ Thomas","year":"2022","unstructured":"Thomas NJ, Myall NJ, Sun F et al (2022) Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol 17:116\u2013129. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.009","journal-title":"J Thorac Oncol"},{"key":"5626_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2023.02.005","volume":"178","author":"E Miao","year":"2023","unstructured":"Miao E, Eichholz JE, Lebow ES et al (2023) Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. Lung Cancer 178:57\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.005","journal-title":"Lung Cancer"},{"key":"5626_CR41","doi-asserted-by":"publisher","first-page":"e2457483","DOI":"10.1001\/jamanetworkopen.2024.57483","volume":"8","author":"E Ferraro","year":"2025","unstructured":"Ferraro E, Reiner AS, Bou Nassif R et al (2025) Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease. JAMA Netw Open 8:e2457483. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57483","journal-title":"JAMA Netw Open"},{"key":"5626_CR42","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol 38:3773\u20133784. https:\/\/doi.org\/10.1200\/JCO.20.01255","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05626-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:40:40Z","timestamp":1781012440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05626-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5626"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05626-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SGB, AT, SYW, MW, VT, and SMR do not have any conflicts to report. LRGP has received grants or contracts from the Department of Defense for the Lung Idea Award for Brain Mets Research, Caris Life Sciences for IIT Genomic Sequencing, and Harbinger Health, Genece Health, and Delfi Diagnostics for early detection trials. He also received consulting fees from Dxcover Limited, Genece Health, Inc., and Monograph Capital Advisors. BSI reports research grants (to institution) from Novartis, Kazia Therapeutics, GT Medical Technologies, AstraZeneca, and Bayer outside the submitted work. BSI serves as a consultant to GT Medical Technologies. NSM received honoraria from Daiichi Sankyo, GT Medical Technologies, and Varian, and research funding from AstraZeneca, Amgen, GT Medical Technologies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}